Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV) posted its quarterly earnings data on Wednesday. The company reported $12.85 EPS for the quarter, topping the consensus estimate of ($0.03) by $12.88, FiscalAI reports.

Here are the key takeaways from Enlivex Therapeutics’ conference call:

• Enlivex reported $1.23 billion in net income and $25.48 EPS for 2025, which management says was driven primarily by market‑based revaluation of its prediction‑markets treasury (RAIN token).
• The company holds an exclusive option to acquire up to 275 billion RAIN tokens at $0.0033 (exercise window extended to Dec 31, 2027), announced a $21 million financing to buy 3 billion RAIN for $10 million, and issued a convertible note with a 90‑day non‑convertible period and a high conversion premium plus a board‑approved up to $20 million share repurchase program.
• FDA cleared an IND for a late‑stage Phase IIb trial of Allocetra in knee osteoarthritis, with 3‑ and 6‑month top‑line data expected in 2027 and the company framing Allocetra as a key clinical value driver.
• Results and valuation gains are concentrated in a nascent, volatile prediction‑markets token (RAIN), making the 2025 GAAP profits potentially non‑repeatable and leaving the company exposed to token market swings and continued public‑market NAV discounts.

Enlivex Therapeutics Stock Performance

ENLV stock traded up $0.11 during trading on Wednesday, reaching $1.21. The company had a trading volume of 7,433,483 shares, compared to its average volume of 414,734. The company has a market cap of $286.04 million, a price-to-earnings ratio of -2.25 and a beta of 1.55. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The firm has a 50-day simple moving average of $1.09 and a 200-day simple moving average of $1.02.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. HC Wainwright raised their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its holdings in shares of Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after buying an additional 156,336 shares during the last quarter. HRT Financial LP raised its stake in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after acquiring an additional 135,198 shares during the last quarter. Jane Street Group LLC raised its stake in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. XTX Topco Ltd lifted its position in Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the period. Finally, Invesco Ltd. purchased a new stake in Enlivex Therapeutics during the 4th quarter valued at about $43,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.